Results 191 to 200 of about 82,056 (314)

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Evaluation of a 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-induced mouse model in a comparative experimental study of portal hypertension. [PDF]

World J Gastroenterol
Zhao JB, Wu ZH, Lin JY, Luo GQ, Zhang CH, Wu GB, Fan Q, Qi XL, Huo HZ, Yu JW, Li HJ, Zheng L, Luo M.   +12 more
europepmc   +1 more source

[Primary biliary cirrhosis: liver transplantation].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1999
M, Hirata, Y, Harihara, M, Makuuchi
openaire   +1 more source

Growth differentiation factor 15 mitigates lipotoxic steatosis by preserving mitochondrial morphodynamics and augmenting fatty acid oxidation in hepatocytes and liver organoids

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Growth differentiation factor 15 (GDF15) has emerged as a promising metabolic regulator with hepatoprotective properties in metabolic dysfunction‐associated steatotic liver disease (MASLD), yet its underlying mechanisms remain elusive.
Jia Li, Qi Zhou, Mengmeng Xia, Yakun Li, Junyu Wang, Manon Buist‐Homan, Vincent E. de Meijer, Hans Blokzijl, Klaas Nico Faber, Han Moshage   +9 more
wiley   +1 more source

Liver Cirrhosis and In-Hospital Outcomes in Patients With Sickle Cell Crises. [PDF]

EJHaem
Gold-Olufadi S, Ogunniyi K, Dorcas AO, Tabiti BF, Saparov D, Nwachukwu C, Becerra H, Bhavanam S, Neharika S, Ogedegbe J, Uche IN, Wang JC, Emeasoba CM, Jaamour D, Awoyemi T.   +14 more
europepmc   +1 more source

Associations between use of aspirin and magnetic resonance imaging‐derived liver fat and fibroinflammation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background The effects of aspirin on hepatic steatosis and fibroinflammation are unclear. The study aimed to examine the association between aspirin use and liver magnetic resonance imaging (MRI)‐derived liver fat and corrected T1 (cT1). Methods We used UK Biobank imaging cohort data.
Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Jun Liu, Mark Woodward   +4 more
wiley   +1 more source

Upregulated beta-defensin-1 in murine and human biliary atresia associates with human native liver survival. [PDF]

Sci Rep
Slavetinsky C, Basenach J, Damm P, Bertolini C, Holweg M, Hartleif S, Hilberath J, Singer S, Petersen C, Fuchs J, Sturm E.   +10 more
europepmc   +1 more source

Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Excess adiposity and obesity are increasingly prevalent, with incidence rising in many parts of the world; both trigger a state of metabo‐inflammation in adipose tissue, creating a systemic milieu characterised by insulin resistance and pro‐inflammatory and fibrogenic states. Along with systemic inflammatory cues, perturbations in systemic and
Mirjana Grocic, Madison Nguyen, Arun J. Sanyal   +2 more
wiley   +1 more source

Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation. [PDF]

JHEP Rep
Frolkis AD, Nayagam JS, Parente A, Seager M, Sadler MD, Montano-Loza AJ, Joshi D.   +6 more
europepmc   +1 more source

Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The burden of chronic liver disease (CLD) is increasing. This study aims to identify protein markers for CLD and its progression, and develop a protein‐based risk prediction model. Materials and Methods We used proteome‐wide Mendelian randomization (MR), Bayesian colocalization and summary‐data‐based MR with proteomic data from deCODE ...
Xinxuan Li, Jing Sun, Jianhui Zhao, Fangyuan Jiang, Meng Zhang, Hao Wu, Shuai Yuan, Xue Li, Juan Lu, Christos S. Mantzoros   +9 more
wiley   +1 more source